Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms: N-Hydroxynicotinamide
Nicoxamat
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | Nicoxamat (N-Hydroxynicotinamide) is an inhibitor of HCV and a selective inhibitor of HDAC6. It is utilized in studies related to hepatitis C virus (HCV) infection. |
| In vitro | Nicoxamat (compound IIa) inhibits the proliferation of HCV replicons in Huh7 luc/neo cells with an EC₅₀ of 25 μM, and a CC₅₀ of 450 μM, resulting in a selectivity index of 18. At concentrations ranging from 20-100 μM, Nicoxamat induces concentration-dependent hyperacetylation of α-tubulin in these cells. However, at 100 μM over 72 hours, it does not significantly acetylate histone H3, indicating selectivity for Class I HDAC. Additionally, within the same concentration range (0-100 μM), Nicoxamat demonstrates a concentration-dependent ability to inhibit HCV replicons and HDAC6 activity, with its antiviral effect being stronger than its HDAC6 inhibition at lower concentrations. |
| Synonyms | N-Hydroxynicotinamide |
| Molecular Weight | 138.12 |
| Formula | C6H6N2O2 |
| Cas No. | 5657-61-4 |
| Smiles | O=C(NO)C=1C=NC=CC1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.